Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma

Autor: Ghassan K. Abou-Alfa, Kristen Bibeau, Nikolaus Schultz, Amin Yaqubie, Brittanie Millang, Haobo Ren, Luis Féliz

Publikováno v: Targeted Oncology. 17:517-527

First-line standard-of-care therapy for advanced cholangiocarcinoma is gemcitabine plus cisplatin; there is no established second-line systemic therapy. Fibroblast growth factor receptor (FGFR)-2 fusions/rearrangements can be oncogenic drivers, occur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::880765dd44a938c5ca3d8ee5caf95cee
https://doi.org/10.1007/s11523-022-00906-w

Data from Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

Autor: Timothy C. Burn, Davide Melisi, Camilla Zecchetto, Luis Féliz, Huiling Zhen, Robert C. Newton, Sherry Owens, Luc Friboulet, Antoine Hollebecque, Ian M. Silverman

Pemigatinib, a selective FGFR1–3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions/rearrangements, and has gained regulatory approval in the United States. Elig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da035ad9df6005abe4dff9fbc887b35c
https://doi.org/10.1158/2159-8290.c.6548233.v1

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Autor: Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M. Kas, Frank Rolfs, Catrin Lutz, Jessica K. Lee, Sjoerd Klarenbeek, Ian M. Silverman, Stefano Annunziato, Chang S. Chan, Sander R. Piersma, Timo Eijkman, Madelon Badoux, Ewa Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, Richard R. de Goeij-de Haas, Gregory M. Riedlinger, Hua Ke, Russell Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, Linda Henneman, Martine H. van Miltenburg, Natalie Proost, Huiling Zhen, Ellen Wientjens, Roebi de Bruijn, Julian R. de Ruiter, Ute Boon, Renske de Korte-Grimmerink, Bastiaan van Gerwen, Luis Féliz, Ghassan K. Abou-Alfa, Jeffrey S. Ross, Marieke van de Ven, Sven Rottenberg, Edwin Cuppen, Anne Vaslin Chessex, Siraj M. Ali, Timothy C. Burn, Connie R. Jimenez, Shridar Ganesan, Lodewyk F. A. Wessels, Jos Jonkers

Publikováno v: Zingg, Daniel; Bhin, Jinhyuk; Yemelyanenko, Julia; Kas, Sjors M; Rolfs, Frank; Lutz, Catrin; Lee, Jessica K; Klarenbeek, Sjoerd; Silverman, Ian M; Annunziato, Stefano; Chan, Chang S; Piersma, Sander R; Eijkman, Timo; Badoux, Madelon; Gogola, Ewa; Siteur, Bjørn; Sprengers, Justin; de Klein, Bim; de Goeij-de Haas, Richard R; Riedlinger, Gregory M; ... (2022). Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature, 609(7929), E13. Springer Nature 10.1038/s41586-022-05287-8

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42007ac1db1800b2f49158a1d120fdb2

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with

Autor: Tanios S, Bekaii-Saab, Juan W, Valle, Eric, Van Cutsem, Lorenza, Rimassa, Junji, Furuse, Tatsuya, Ioka, Davide, Melisi, Teresa, Macarulla, John, Bridgewater, Harpreet, Wasan, Mitesh J, Borad, Ghassan K, Abou-Alfa, Ping, Jiang, Christine F, Lihou, Huiling, Zhen, Ekaterine, Asatiani, Luis, Féliz, Arndt, Vogel

Publikováno v: Future oncology (London, England). 16(30)

FGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA. Pemigatinib, a selective, potent, oral inhibitor of FGFR1-3, has demonstrated efficacy a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::98e7816bfea37b17ed2bf341f75c4654
https://pubmed.ncbi.nlm.nih.gov/32677452

Pemigatinib for Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma

Autor: David Gallinson, Arndt Vogel, Adrian Murphy, Tao Ji, Davide Melisi, Hui-Ling Zhen, Christine F. Lihou, Daniel V.T. Catenacci, Vaibhav Sahai, Eric Van Cutsem, Luis Féliz, Ghassan K. Abou-Alfa, Do-Youn Oh, Efrat Dotan, A. Hollebecque, Gina M. Vaccaro, Andrew Scott Paulson, Mitesh J. Borad, Raed Al-Rajabi

Publikováno v: SSRN Electronic Journal.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6ea3af0d8a91bc2a0476bb68558fb14d
https://doi.org/10.2139/ssrn.3489302